MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12325-026-03582-8

Медицинская библиотека · Advances in therapy · 2026

Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension Study.

Beck Lisa A, Simpson Eric L, Thaçi Diamant, de Bruin-Weller Marjolein, Deleuran Mette, Kataoka Yoko, Blauvelt Andrew, Wollenberg Andreas, Eichenfield Lawrence F, Khokhar Faisal A, Coleman Anna, Van Spall Michael, Ma Yonghao, Avetisova Elena, Zhang Annie, Nguyen Tien V

СтатьяРандомизированное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

INTRODUCTION

Patients with atopic dermatitis (AD) are at an increased risk for infections. Here, we report a confirmatory follow-up study analyzing the incidence of infections in adults with moderate-to-severe AD treated with dupilumab for up to 5 years.

METHODS

Infections in adults with moderate-to-severe AD treated with dupilumab 300 mg weekly (qw) or every 2 weeks (q2w; approved regimen) were assessed for up to 5 years in the open-label extension study, LIBERTY AD OLE. Topical corticosteroids (TCS) and calcineurin inhibitors (TCI) were permitted. Exposure-adjusted incidence rates [number of patients with at least one event per 100 patient-years (nP/100 PY)] are reported. Since the OLE had no control arm, safety results from the placebo + TCS arm of the 1-year LIBERTY AD CHRONOS study are included for comparisons.

RESULTS

Of the 2677 patients included, 2207 (82.4%) completed up to week 52, 557 (20.8%) up to week 148, and 334 (12.5%) up to week 260; 226 patients (8.4%) switched from qw to q2w during the trial due to a protocol amendment. Overall infections (70.69 nP/100 PY), serious infections (0.87 nP/100 PY), severe infections (0.92 nP/100 PY), and infections leading to treatment discontinuation (0.34 nP/100 PY) were consistent with previous 4-year open-label extension (OLE) analyses and were low compared with 1-year results from the CHRONOS placebo + TCS arm. The cumulative number of patients with treatment-emergent serious or severe infections, non-herpetic or herpetic infections, and total skin infections decreased throughout the OLE study period. Limitations of this study include the absence of a placebo arm in the OLE, decreasing sample size at later time points, inclusion of qw dosing analyses (different from approved q2w dosing), and possible confounding effects of TCS/TCI use that may impact infection rates.

CONCLUSIONS

Long-term dupilumab treatment for up to 5 years in adults with moderate-to-severe AD is not associated with an increased overall risk of infections. Graphical abstract available for this article.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01949311, NCT02260986.

Для цитирования: Beck Lisa A, Simpson Eric L, Thaçi Diamant, de Bruin-Weller Marjolein, Deleuran Mette, Kataoka Yoko, Blauvelt Andrew, Wollenberg Andreas, Eichenfield Lawrence F, Khokhar Faisal A, Coleman Anna, Van Spall Michael, Ma Yonghao, Avetisova Elena, Zhang Annie, Nguyen Tien V. Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension Study.. Advances in therapy. 2026. DOI: 10.1007/s12325-026-03582-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.